GlassScriptPhysician profile
Roberto Pisoni
NPI 1699978098
$6,735.56
in general payments reported to CMS, 2019-2025
8 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572 · 2020: $95.51 · 2023: $4,798 · 2024: $16.89 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,141 · Travel and Lodging: $537 · Food and Beverage: $373 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,141.00 |
| Travel and Lodging | $537.33 |
| Food and Beverage | $373.21 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $4,893.06 | 2020-2023 | Jynarque, Tolvaptan |
| Vertex Pharmaceuticals Incorporated | $1,430.92 | 2019 | |
| Mallinckrodt Enterprises LLC | $140.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $131.43 | 2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $122.56 | 2025 | Tarpeyo |
| Travere Therapeutics, INC. | $16.89 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Pisoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.